All In Biotech

Drug Trial Radar · NCT04302025

A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)

NAUTIKA1: A Multicenter, Phase II, Neoadjuvant and Adjuvant Study of Multiple Therapies in Biomarker-selected Patients With Resectable Stages IB-III Non-small Cell Lung Cancer

Last checked: Nov 19, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

99

Planned (sponsor's estimate)

Start

Nov 6, 2020

Primary completion

Nov 30, 2026

Study completion May 30, 2030

Sponsor

Lead sponsor
Genentech, Inc.Roche (Genentech) (RHHBY)
Sponsor type
Industry
First posted
Mar 10, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This trial will evaluate the efficacy and safety of various therapies in participants with Stage IB, IIA, IIB, IIIA, or selected IIIB resectable and untreated NSCLC tumors that meet protocol-specified biomarker criteria.

Conditions

  • Non-small Cell Lung Cancer

Interventions

  • AlectinibDrug

    Participants will receive oral alectinib twice per day (BID).

  • EntrectinibDrug

    Participants will receive oral entrectinib daily.

  • VemurafenibDrug

    Participants will receive oral vemurafenib BID.

  • CobimetinibDrug

    Participants will receive oral cobimetinib daily.

  • PralsetinibDrug

    Participants will receive oral pralsetinib daily.

  • AtezolizumabDrug

    Atezolizumab will be administered by intravenous (IV) infusion.

  • SBRTDrug

    Participants will receive SBRT given concurrently, starting with the first dose of atezolizumab.

  • ResectionProcedure

    Participants will receive surgical resection of the primary tumor along with selected lymph nodes per SOC.

  • ChemotherapyDrug

    Participants will receive SOC chemotherapy as determined by the treating physician.

  • DivarasibDrug

    Participants in the KRAS G12C cohort will receive oral divarasib for approximately 8 weeks until the day before surgery as neoadjuvant therapy up to 3 years as adjuvant therapy.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Tyrosine Kinase Inhibitor (TKI) Cohort: Proportion of Participants With Major Pathologic Response (MPR)Time frame: After surgical resection (approximately study Week 8)
  2. Checkpoint Inhibitor (CPI) Cohort: Pathological Complete Response (pCR)Time frame: After surgical resection (approximately study Week 8)
  3. KRAS G12C Cohort: Percentage of Participants With 3-5 Grade Adverse Events (AEs)Time frame: After surgical resection (approximately study Week 8)
  4. KRAS G12C Cohort: Percentage of Participants Without Delays of Surgery due to Treatment-related AEs as Reported by the InvestigatorTime frame: After surgical resection (approximately study Week 8)

Locations

24 sites in 1 country. Site status is shown where the registry gives one.

  • University of California Los Angeles - Jonsson Comprehensive Cancer Center

    Los Angeles, California

  • The Center for Cancer Prevention and Treatment at St.Joseph Hospital of Orange

    Orange, California

  • UC Davis Comprehensive Cancer Center

    Sacramento, California

  • Yale Cancer Center

    New Haven, Connecticut

  • MedStar Georgetown University Hospital (Lombardi Comprehensive Cancer Center)

    Washington D.C., District of Columbia

  • Moffitt Cancer Center

    Tampa, Florida

  • Northwestern University

    Chicago, Illinois

  • Northwestern Medicine Cancer Center Kishwaukee

    DeKalb, Illinois

  • Northwestern Medicine Cancer Center Delnor

    Geneva, Illinois

  • Northwestern Medicine Cancer Center Warrenville

    Warrenville, Illinois

  • Dana-Farber Cancer Institute

    Boston, Massachusetts

  • University of Michigan

    Ann Arbor, Michigan

  • Mayo Clinic

    Rochester, Minnesota

  • Ellis Fischel Cancer Center

    Columbia, Missouri

  • Siteman Cancer Center - Washington University Medical Campus

    St Louis, Missouri

  • Dartmouth Hitchcock Medical Center

    Lebanon, New Hampshire

  • Laura and ISAAC Perlmutter Cancer Center at NYU Langone.

    New York, New York

  • Columbia University Medical Center

    New York, New York

  • Memorial Sloan Kettering Cancer Center

    New York, New York

  • Ohio State University

    Columbus, Ohio

  • AHN Cancer Institute ? Allegheny General Hospital

    Pittsburgh, Pennsylvania

  • Baptist Clinical Research Institute

    Memphis, Tennessee

  • University of Texas MD Anderson Cancer Center

    Houston, Texas

  • Virginia Cancer Specialists (Fairfax) - USOR

    Fairfax, Virginia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.